CoChat
Sign Up
Cited by 72Cervical Cancer and HPV ResearchGenital Health and DiseaseReproductive tract infections research

Prevalence of HPV infection among sexually active adolescents and young adults in Brazil: The POP-Brazil Study

Open access
Wendland, Eliana Marcia, Villa, Luisa Lina, Unger, Elizabeth R., Domingues, Carla Magda, Benzaken, Adele Schwartz, POP-Brazil Study Group, Maranhão, Ana Goretti Kalume, Kops, Natalia Luiza +11 more·2020·Scientific Reports
DOI 10.1038/s41598-020-61582-2PMC PMC7080737
Open this paper in CoChat — free accountOpen PDF

Abstract

For Brazil, there are no nationwide data on HPV prevalence against which the impact of the HPV immunization program can be measured in the future. Therefore, we aim to evaluate the prevalence of genital HPV infection among adolescents and young adults in Brazil. A cross-sectional, multicentric, nationwide survey was conducted between September 2016 and November 2017. Sexually active unvaccinated women and men aged 16 to 25 years old were recruited from 119 public primary care units, including all 26 state capitals and the Federal District. All participants answered a face-to-face interview and provided biological samples for genital HPV analysis. We used an automated DNA extraction method and HPV genotyping was performed using the Linear Array genotyping test (Roche). Of 7,694 participants, 53.6% (95% CI 51.4–55.8) were positive for any HPV type. The prevalence of high-risk HPV types was significantly higher in women (38.6% vs. 29.2%, P < 0·001). The HPV types included in the quadrivalent vaccine were detected in 1002 (14.8%) specimens, with a different pattern of HPV infection between sexes. Characteristics associated with overall HPV detection included female gender, self-declaration of race as brown/pardo, lower socioeconomic class, single or dating, current smoking and having 2 or more sex partners in the past year. We found a high prevalence of HPV, with significant differences between regions. Our data provide information that may be considered when developing HPV prevention policies and constitute a baseline against which the impact of the HPV immunization program in Brazil can be measured in future years.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-61582-2

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 36

  1. [1]Forman D Global Burden of Human Papillomavirus and Related Diseases Vaccine 2012 30 F12 F23 10.1016/j.vaccine.2012.07.055 23199955 · DOI
  2. [2]Bosch FX Lorincz A Muñoz N Meijer CJLM Shah KV The causal relation between human papillomavirus and cervical cancer J. Clin. Pathol. 2002 55 244 265 10.1136/jcp.55.4.244 11919208 PMC1769629 · DOI
  3. [3]Chaturvedi AK Global burden of human papillomavirus-positive head and neck cancers Lancet Oncol. 2014 15 1282 1283 10.1016/S1470-2045(14)71029-0 25439682 · DOI
  4. [5]Ginsburg OM Breast and cervical cancer control in low and middle-income countries: Human rights meet sound health policy J. Cancer Policy 2013 1 e35 e41 10.1016/j.jcpo.2013.07.002 · DOI
  5. [6]Bruni L Cervical Human Papillomavirus Prevalence in 5 Continents: Meta−Analysis of 1 Million Women with Normal Cytological Findings J. Infect. Dis. 2010 202 1789 1799 10.1086/657321 21067372 · DOI
  6. [7]Fonseca AJ HPV Infection and Cervical Screening in Socially Isolated Indigenous Women Inhabitants of the Amazonian Rainforest PLOS ONE 2015 10 e0133635 10.1371/journal.pone.0133635 26207895 PMC4514624 · DOI
  7. [10]Garland SM Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases N. Engl. J. Med. 2007 356 1928 1943 10.1056/NEJMoa061760 17494926 · DOI · Paper page
  8. [11]Hildesheim A Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial Vaccine 2014 32 5087 5097 10.1016/j.vaccine.2014.06.038 25018097 PMC4166498 · DOI
  9. [12]Lehtinen M Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials BMJ Open 2017 7 e015867 10.1136/bmjopen-2017-015867 PMC5629648 28821519 · DOI
  10. [13]Howell-Jones R Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation Vaccine 2012 30 3867 3875 10.1016/j.vaccine.2012.04.006 22516212 · DOI
  11. [14]Kavanagh, K. et al. Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infect. Dis. 13 (2013). PMC4228358 24188790
  12. [15]Dickson EL Vogel RI Bliss RL Downs LS Multiple-Type Human Papillomavirus (HPV) Infections: A Cross-Sectional Analysis of the Prevalence of Specific Types in 309,000 Women Referred for HPV Testing at the Time of Cervical Cytology Int. J. Gynecol. Cancer 2013 23 1295 1302 10.1097/IGC.0b013e31829e9fb4 23970156 PMC3882063 · DOI
  13. [16]Wheeler CM A population-based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination Int. J. Cancer 2013 132 198 207 10.1002/ijc.27608 22532127 PMC3852415 · DOI
  14. [17]The WHINURS study group et al. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med. 9 (2011). PMC3182900 21910918
  15. [18]Hariri S Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006 J. Infect. Dis. 2011 204 566 573 10.1093/infdis/jir341 21791659 · DOI
  16. [19]Markowitz LE Prevalence of HPV After Introduction of the Vaccination Program in the United States PEDIATRICS 2016 137 e20151968 e20151968 10.1542/peds.2015-1968 26908697 · DOI
  17. [20]Wendland EM POP-Brazil study protocol: a nationwide cross-sectional evaluation of the prevalence and genotype distribution of human papillomavirus (HPV) in Brazil BMJ Open 2018 8 e021170 10.1136/bmjopen-2017-021170 PMC6009568 29880568 · DOI
  18. [22]Steinau M Swan DC Unger ER Type-specific reproducibility of the Roche linear array HPV genotyping test J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 2008 42 412 414 10.1016/j.jcv.2008.03.004 18424229 · DOI
  19. [23]Stevens MP Garland SM Tabrizi SN Validation of an Automated Detection Platform for Use with the Roche Linear Array Human Papillomavirus Genotyping Test J. Clin. Microbiol. 2008 46 3813 3816 10.1128/JCM.01169-08 18784316 PMC2576620 · DOI
  20. [25]Onyekwuluje JM Steinau M Swan DC Unger ER A real-time PCR assay for HPV52 detection and viral load quantification Clin. Lab. 2012 58 61 66 22372346
  21. [30]da Silva MC Prevalence of HPV infection and genotypes in women with normal cervical cytology in the state of Paraná, Brazil Arch. Gynecol. Obstet. 2012 286 1015 1022 10.1007/s00404-012-2399-y 22699514 · DOI
  22. [31]Chagas BS Association Study between Cervical Lesions and Single or Multiple Vaccine-Target and Non-Vaccine Target Human Papillomavirus (HPV) Types in Women from Northeastern Brazil PLOS ONE 2015 10 e0132570 10.1371/journal.pone.0132570 26176537 PMC4503727 · DOI · Paper page
  23. [33]Ayres ARG Silva GAe Prevalência de infecção do colo do útero pelo HPV no Brasil: revisão sistemática Rev. Saúde Pública 2010 44 963 974 10.1590/S0034-89102010000500023 20877926 · DOI
  24. [34]Giuliano AR The Human Papillomavirus Infection in Men Study: Human Papillomavirus Prevalence and Type Distribution among Men Residing in Brazil, Mexico, and the United States Cancer Epidemiol. Biomarkers Prev. 2008 17 2036 2043 10.1158/1055-9965.EPI-08-0151 18708396 PMC3471778 · DOI
  25. [35]Lewis RM Markowitz LE Gargano JW Steinau M Unger ER Prevalence of Genital Human Papillomavirus Among Sexually Experienced Males and Females Aged 14–59 Years, United States, 2013–2014 J. Infect. Dis. 2018 217 869 877 10.1093/infdis/jix655 29294016 PMC5991084 · DOI
  26. [36]Bouvard V A review of human carcinogens—Part B: biological agents Lancet Oncol. 2009 10 321 322 10.1016/S1470-2045(09)70096-8 19350698 · DOI · Paper page
  27. [37]Hirth J Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14–26 year old females in the U.S Vaccine 2018 36 7682 7688 10.1016/j.vaccine.2018.10.075 30377066 PMC6289515 · DOI
  28. [38]Hibbitts S Human papillomavirus infection: an Anonymous Prevalence Study in South Wales, UK Br. J. Cancer 2006 95 226 232 10.1038/sj.bjc.6603245 16819542 PMC2360618 · DOI
  29. [39]Akogbe GO Race and prevalence of human papillomavirus infection among men residing in Brazil, Mexico and the United States Int. J. Cancer 2012 131 E282 E291 10.1002/ijc.27397 22161806 PMC3458422 · DOI
  30. [40]Lin L Racial and ethnic differences in human papillomavirus positivity and risk factors among low-income women in Federally Qualified Health Centers in the United States Prev. Med. 2015 81 258 261 10.1016/j.ypmed.2015.08.027 26361751 PMC4751981 · DOI
  31. [41]Nejo YT Olaleye DO Odaibo GN Prevalence and Risk Factors for Genital Human Papillomavirus Infections Among Women in Southwest Nigeria Arch. Basic Appl. Med. 2018 6 105 112 29905313 PMC5997288
  32. [42]Schabath MB Smoking and human papillomavirus (HPV) infection in the HPV in Men (HIM) study Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 2012 21 102 110 10.1158/1055-9965.EPI-11-0591 PMC3253903 22016473 · DOI
  33. [43]Vaccarella S Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys Int. J. Epidemiol. 2008 37 536 546 10.1093/ije/dyn033 18316350 · DOI
  34. [44]Winer RL Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students Am. J. Epidemiol. 2003 157 218 226 10.1093/aje/kwf180 12543621 · DOI
  35. [45]Giuliano AR Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States) Cancer Causes Control CCC 2002 13 839 846 10.1023/A:1020668232219 12462549 · DOI
  36. [46]Machalek, D. A. et al. Human papillomavirus prevalence in unvaccinated heterosexual males following a national female vaccination program. J. Infect. Dis. jiw530, 10.1093/infdis/jiw530 (2016). 27815379 · DOI

Cited by

Sorted by citations

Authors
Wendland, E. M., Villa, L. L., Unger, E. R., Domingues, C. M., Benzaken, A. S., POP-Brazil Study Group, Maranhão, A. G. K., Kops, N. L., Bessel, M., Caierão, J., Hohenberger, G. F., Horvath, J., Tavares, G., Mello, B. P., Santos, A. V. D., Berto, M. D., Bica, C., Pereira, G. F. M., & Moreno, F.
Affiliations
  • Universidade Federal de Ciências da Saúde de Porto Alegre (BR)
  • Universidade de São Paulo (BR)
  • Centers for Disease Control and Prevention (US)
  • Ministério da Saúde (BR)
  • Fundação de Medicina Tropical (BR)
  • Hospital Moinhos de Vento (BR)
  • Universidade Federal do Rio Grande do Sul (BR)
Corresponding author
Wendland, Eliana Marcia
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2020-03-18
Volume
10
Issue
1
Pages
4920-4920
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/s41598-020-61582-2
PMC
PMC7080737
OpenAlex
W3011030403
Cited by
72
References
2
Citations by year
2026: 7 · 2025: 6 · 2024: 18 · 2023: 9 · 2022: 12 · 2021: 14 · 2020: 6
FWCI
7.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Luisa Lina Villa is a member of the Board for HPV vaccines for Merck, Sharp & Dohme and a consultant for BD, Roche, and Qiagen for HPV tests.
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Surgery › Genital Health and Disease
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords
HPV infection, adolescents and young adults, high-risk HPV, HPV genotyping, quadrivalent HPV vaccine, sex differences, smoking, multiple sexual partners, socioeconomic status, regional variation
MeSH terms
Adolescent, Adult, Brazil, Cross-Sectional Studies, Female, Genotype, Humans, Male, Mass Screening, Sexually Transmitted Diseases, Viral, Prevalence, Papillomaviridae, Papillomavirus Infections, Young Adult, Public Health Surveillance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review